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Abstract
The human gut contains trillions of symbiotic bacteria that play a key role in programming different aspects of host physiology in
health and disease. Psychotropic medications act on the central nervous system (CNS) and are used in the treatment of various
psychiatric disorders. There is increasing emphasis on the bidirectional interaction between drugs and the gut microbiome. An
expanding body of evidence supports the notion that microbes can metabolise drugs and vice versa drugs can modify the gut
microbiota composition. In this review, we will first give a comprehensive introduction about this bidirectional interaction, then
we will take into consideration different classes of psychotropics including antipsychotics, antidepressants, antianxiety drugs,
anticonvulsants/mood stabilisers, opioid analgesics, drugs of abuse, alcohol, nicotine and xanthines. The varying effects of these
widely used medications on microorganisms are becoming apparent from in vivo and in vitro studies. This has important
implications for the future of psychopharmacology pipelines that will routinely need to consider the host microbiome during
drug discovery and development.
Keywords Psychotropic . Antipsychotic . Antidepressant . Antimicrobial . Gut microbiome
Introduction
In the second instalment of J.K. Rowling’s Harry Potter book
series, the trainee wizards encounter a magical Chamber of
Secrets deep within the Hogwarts School. In some ways, this
story parallels the human body, with the gastrointestinal tract
hidden within and guarding many secrets.
The human gastrointestinal tract harbours trillions of mi-
crobes, the gut microbiota, which help modulate developmen-
tal, immunological and nutritional function in the host
(Bengmark 2013; Sampson and Mazmanian 2015; Soto
et al. 2018; Valdes et al. 2018; Wang et al. 2016). The coloni-
sation of the gut is generally believed to begin at birth with the
infant initially receiving microbial colonisation from the
mother as it passes through the birth canal, although this no-
tion has been challenged by a limited number of studies in
which microbes were detected in the placenta (Aagaard et al.
2014; Collado et al. 2016; DiGiulio 2012). In a recent review
paper, a critical assessment of the evidence supporting these
two opposing hypotheses has been carried out and the authors
argue that the evidence in support of the Bin utero colonization
hypothesis^ is conceptually and materially flawed (Perez-
Muñoz et al. 2017). Events such as illness, antibiotic treatment
and changes in diet cause shifts in the microbiota (Codagnone
et al. 2018; Conlon and Bird 2015; De Filippo et al. 2010;
Rodrigues et al. 2017; Wang et al. 2017). Mode of delivery at
birth also affects the microbiota composition, with vaginally
delivered infants containing a high abundance of lactobacilli
during the first few days, a reflection of the high load of
lactobacilli in the vaginal flora (Aagaard et al. 2012;
Avershina et al. 2014). In early stages of development, the
microbiota is generally low in diversity and is dominated by
two main phyla, Actinobacteria and Proteobacteria
(Rodriguez et al. 2015). During the first year of life, the mi-
crobial diversity increases and by around 2.5 years of age, the
composition, diversity and functional capabilities of the infant
microbiota resemble those of an adult microbiota (Koenig
et al. 2011; Rodriguez et al. 2015). In individuals over the
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age of 65, the microbial community changes, with an in-
creased abundance of Bacteroidetes phyla and Clostridium
cluster IV, in contrast with younger subjects where the cluster
XIVa is more prevalent (Claesson et al. 2011). It has been
demonstrated that the microbiota of young adults and 70-
year-old people is highly similar but differs significantly from
that of centenarians (Biagi et al. 2010).
The role of the microbiota in health and disease has
stretched to all disciplines of medicine and this now includes
pharmacology and therapeutics (Walsh et al. 2018). The field
of pharmacomicrobiomics has emerged over the past decade
(ElRakaiby et al. 2014; Saad et al. 2012) and has predomi-
nantly focused on the impact that the gut microbiota exerts on
drug metabolism. Also, a growing body of research has dem-
onstrated that several pharmaceutical compounds, including
paracetamol, digoxin, metformin and cancer drugs among
others, influence the human gut microbiota and/or microbial
isolated strains. As bacteria can, in turn, modulate drug effi-
cacy and toxicity (Alexander et al. 2017; Currò 2018; Li et al.
2016), the emerging drug-microbe bidirectional interaction
might be crucial for future drug development and clinical
practice. Moreover, this suggests that drug-related confound-
ing effects should be taken into consideration in future
microbiome association studies.
In this review, we will focus on psychotropic compounds
(from the Greek root psychè = mind and tropòs = turning),
which modulate brain and behaviour, and we will explore the
scientific evidence on the interaction between psychotropic
compounds and the gut microbiome in vivo or in isolated
strains (in vitro) (Fig. 1). For each class of psychotropic com-
pound taken into consideration, sub-sections will be based on
the experimental approach used (observations in vitro, in vivo
or in humans). Regarding in vitro experiments, some attempts
have been made to try and find the best dose translational to
the human gut setting. Maier and colleagues have deduced
colon concentrations on the basis of drug excretion patterns
from published work and small intestine concentrations on the
basis of daily doses of individual drugs. Based on their ap-
proximations, a threshold of 20 μM was below the median
small intestine and colon concentration of the majority of
human-targeted drugs (Maier et al. 2018). It is important to
keep this in mind when considering data generated from
in vitro isolated microbial strains.
The literature search (PubMed) was conducted using
the following terms as inclusion criteria: the chemical name
of each drug belonging to either of the following classes:
antipsychotics, antidepressants, antianxiety drugs, anti-
convulsants/mood stabilisers, opioid analgesics, drugs of
abuse OR alcohol/ethanol OR nicotine OR xanthines (caf-
feine, theobromine, theophylline) AND (gut microbiome OR
gut microbiota OR antimicrobial) up to 20 January 2019.
Reviews, meta-analyses and systematic reviews were omitted
from the search strategy.
Drugs affect the gut microbiota
In Rowling’s book, the trainee wizards eventually find the
gate to the Chamber of Secrets; similarly, xenobiotic com-
pounds belonging to several therapeutic classes can reach
the Chamber and affect what is hidden within, our gut
microbiota.
Antibiotics represent the most direct and effective way of
targeting intestinal microbes. Evidence gathered from in vitro
and in vivo studies suggests that a course of short-term anti-
biotics can substantially change the gut microbiota composi-
tion (Jakobsson et al. 2010; Maurice et al. 2013). Several host-
targeting non-antibiotic drugs have also been shown to influ-
ence the gut microbiota. In a population-based cohort, deep
sequencing of gut microbiomes of 1135 participants showed
relations between the microbiota and 19 drug groups
(Zhernakova et al. 2016). Other studies have pointed out an
association between drug consumption and microbiome.
Analysis of two independent population-level cohorts re-
vealed that, among different factors, the use of medications
was responsible for the largest total variance and interacted
with other covariate-microbiota associations (Falony et al.
2016). The composition of the gut microbiota can change in
relation to the number and type of medications consumed.
Differences in the relative abundance of specific bacteria were
detected in individuals taking a single drug, a combination or
none. In particular, there were differences in the gut microbi-
ota of individuals taking NSAIDs (non-steroidal anti-
inflammatory drugs) with PPIs (proton-pump inhibitors) ver-
sus those taking NSAIDs without PPIs (Rogers and Aronoff
2016). Regarding polypharmacy, in elderly hospitalised pa-
tients, there was a significant negative correlation between
the number of drugs and microbial alpha-diversity (Chao1
index). Moreover, the number of drugs was associated with
the average relative abundance of 15 different taxa, with PPIs,Fig. 1 Psychotropic compounds affect the gut microbiota composition
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antidepressants and antipsychotics exhibiting the strongest as-
sociation with single bacteria abundance (Ticinesi et al. 2017).
The gut microbiota affects
the pharmacokinetics of drugs
According to the novel, the Chamber of Secrets is home of a
giant serpent, the basilisk. Similar to the basilisk, which has
the ability to kill by looking people in the eyes, the microbes
harboured in our guts can influence to a certain extent the
pharmacokinetics of drugs.
Pharmacokinetics (from the Greek root pharmakon = drug
and kinetikos = moving, Bputting in motion^) is a branch of
pharmacology dedicated to determining the fate of xenobi-
otics administered to a living organism. Absorption is one of
the four compartments of the pharmacokinetics multi-
compartmental model (Arundel 1997), together with distribu-
tion, metabolism and excretion (ADME) (Pacey et al. 2011).
In the next two sections, we provide some of the most
compelling evidence on the interaction between gut
microbiome and drug absorption/metabolism prior to
discussing the relevance to psychotropic compounds.
The gut microbiota affects drug absorption
In pharmacology, absorption is the movement of a substance
from the site of administration to the bloodstream (Doogue
and Polasek 2013). Very little is currently known about the
role played by the gut microbiota in drug absorption but a few
reports on the topic exist. It is interesting to note that all the
three studies mentioned in this section use the same experi-
mental approach: manipulation of the gut microbiota through
administration of probiotics.
The action of gliclazide, a sulfonylurea used to treat diabe-
tes, may be enhanced by administering probiotics. In diabetic
rats, the blood levels of gliclazide are higher following a 3-day
pre-treatment with probiotics (at the dose of 75 mg/kg) com-
pared to non-treated rats, suggesting that the gut microbiota
might mediate the extent of the drug absorption (Al-Salami
et al. 2008). In a recent study, a 3-day administration of
Lactobacillus reuteri K8 reduced the absorption of orally ad-
ministered acetaminophen in mice, whereas administration
of Lactobacillus reuteri K9 did not have an effect (Kim
et al. 2018). This effect was probably mediated by probiotic-
induced modulation of gut microbial enzyme activity given
that the probiotic significantly increased both sulfatase and
arylsulfate transferase and significantly decreased β-glucu-
ronidase, which are the bacterial enzymes involved in acet-
aminophen metabolism. Finally, the antiarrhythmic drug
amiodarone shows elevated blood levels following adminis-
tration of probiotics in rats. In details, the probiotic E. coli
strain Nissile 1917 was administered to rats for 7 days,
followed by a single dose of amiodarone per os. The probiotic
increased amiodarone plasmatic levels by 43% compared to
saline-treated controls, suggesting a microbiota-mediated in-
crease in drug absorption (Matuskova et al. 2014).
The gut microbiota affects drug metabolism
The fate of xenobiotics depends not only by the host but also
by the bacteria harbouring our gastrointestinal tract and it has
become more investigated, over the past decades, the role of
gut microbiome in xenobiotic metabolism. The whole field
has been termed Bpharmacomicrobiomics^ (Rizkallah et al.
2010). In this paragraph, we offer a glimpse into the known
effects of the gut microbiota on drug metabolism.
Digoxin, a cardiac glycoside that has been widely used for
hundreds of years to treat heart failure and arrhythmias, is a
striking example. This drug is inactivated in the gut by the
Actinobacterium Eggerthella lenta (Haiser et al. 2013).
Moreover, increased consumption of dietary protein in
germ-free mice inhibited the reduction of digoxin by
E. lenta (Haiser et al. 2013). The microbial biotransformation
of orally administered lovastatin, a drug used for lowering
cholesterol levels and reduce the risk of cardiovascular dis-
ease, was reduced by concomitant administration of antibi-
otics in rats (Yoo et al. 2014). This could result in altered
systemic concentrations of either the intact drug and/or its
metabolites (Yoo et al. 2014).Amlodipine, a medication used
to treat high blood pressure and coronary artery disease, un-
dergoes clearance when incubated with a faecal suspension,
suggesting that the gut microbiota metabolises this drug (Yoo
et al. 2016). As a confirmation, a 2-day treatment with the
antibiotic ampicillin in rats increases the plasma levels of
amlodipine, possibly because of the decreased microbial bio-
transformation in the gastrointestinal tract (Yoo et al. 2016).
Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is
an anti-inflammatory drug used to treat inflammatory bowel
disease, including ulcerative colitis or to maintain remission in
Crohn’s disease (Rachmilewitz 1989). The faecal microbiota
plays a key role in acetylating 5-ASA, with 44% of anaerobic
bacteria tested in incubation with the drug exhibiting this
property (van Hogezand et al. 1992). The metabolism of
sulfasalazine, a drug used for the treatment of rheumatoid
arthritis, ulcerative colitis and Crohn’s disease, is also likely
to be mediated by intestinal bacteria. When sulfasalazine was
fed to conventional rats, none of the drug was recovered in the
urine, faeces or caecum; however, if administered in combi-
nation with the antibiotic neomycin, the drug was recovered in
faeces and the caecum (Peppercorn and Goldman 1972). In
addition, when sulfasalazine was given to germ-free rats, re-
covery of drug in the faeces was over 50% whereas the urine
contained an additional 1–2%. In germ-free rats infected with
four specific bacteria normally found in the intestinal tract of
rodents, sulfasalazine was metabolised as in conventional rats
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(Peppercorn andGoldman 1972). Sulfasalazine ismetabolised
by azoreductases in the gut. The probiotic strains
Lactobacillus acidophilus L10, Bifidobacterium lactis B94
and Streptococcus salivarius K12 given to rats for three con-
secutive days increased azoreductase activity in ex vivo colon
contents with a corresponding increase in sulfasalazine metab-
olism (Lee et al. 2012). Interestingly, however, the same pro-
biotic treatment in rats, followed by an oral 100 mg/kg dose of
sulfasalazine, did not alter the pharmacokinetic parameters
(Lee et al. 2012). Administration of diclofenac, a nonsteroidal
anti-inflammatory drug (NSAID), induced enteropathy in
mice; however, oral pre-treatment with a bacteria-specific β-
glucuronidase inhibitor was able to protect against diclofenac-
induced enteropathy (LoGuidice et al. 2012), suggesting that
the gut microbiota might play a crucial role in the metabolism
of this medication. The antithrombotic effect of aspirin seems
to be affected by the gut microbiota. In rats, administration of
the antibiotic ampicillin significantly prolongs the bleeding
time in aspirin-dosed rats (Kim et al. 2016). Moreover, oral
administration of ampicillin reduces the aspirin-metabolising
activity of the microbiota by 67% (Kim et al. 2016).
Intestinal microbial azoreductases play a key role in the
reduction of azo dyes (Chung et al. 1992). A wide variety of
anaerobic bacteria isolated from caecal or faecal contents from
experimental animals and humans have the ability to cleave
the azo linkages to produce aromatic amines (Chung et al.
1992). Moreover, the azoreductase activity in a variety of
intestinal preparations is affected by various dietary factors
including antibiotics and supplementation with live cultures
of lactobacilli (Chung et al. 1992).
Choline and carnitine are dietary amines that have wide-
ranging roles in human metabolism (Zeisel and da Costa
2009) and are precursors of trimethylamine (TMA), a com-
pound that can cause trimethylaminuria when not appropriate-
ly metabolised by the host (Mackay et al. 2011). In a recent
study, the quantification and detailed characterisation of the
TMA-producing bacteria in human faecal samples have re-
sulted particularly in Clostridium XIVa strains and
Eubacterium sp. strain AB3007 (Rath et al. 2017). In a differ-
ent study, carnitine metabolism was mediated by Rieske-type
oxygenases present in the human microbiota (Zhu et al. 2014).
Chemotherapeutic drugs have also been shown to be
metabolised by the gut microbiota (Alexander et al. 2017).
Of 30 chemotherapeutic drugs examined in vitro, the efficacy
of 10 was found to be significantly inhibited by certain bacte-
ria, while the same bacteria improved the efficacy of six others
(Lehouritis et al. 2015). As further corroboration of these find-
ings, the chemoresistance or increased cytotoxicity observed
in vitro with sample drugs (gemcitabine and CB1954) was
replicated in in vivo murine subcutaneous tumour models
(Lehouritis et al. 2015). The dose-limiting side effect of the
common colon cancer chemotherapeutic irinotecan is severe
diarrhoea that arises following reactivation of the drug by
symbiotic bacterial β-glucuronidases in the gut (Ma and
McLeod 2003; Mathijssen et al. 2001). Oral administration
of a bacterial β-glucuronidase inhibitor protected mice from
irinotecan-induced toxicity, suggesting that such inhibitors
may be designed to prevent undesirable enzyme activities in
the intestine (Wallace et al. 2010). The gut microbiota also
plays a crucial role in the metabolism of 5-fluorouracil, an-
other chemotherapeutic compound (Nakayama et al. 1997).
The antineoplastic drug doxorubicin is effectively
metabolised by Raoultella planticola in vitro, as demonstrated
by Yan and colleagues (Yan et al. 2018). Specifically,
R. planticola was shown to deglycosylate doxorubicin into
i t s me t a bo l i t e s 7 - d eoxydoxo r ub i c i n o l a nd 7 -
deoxydoxorubicinolone via a reductive deglycosylation
mechanism. Moreover, doxorubicin was degraded anaerobi-
cally by Klebsiella pneumoniae and E. coli BW25113 in vitro
(Yan et al. 2018). In a recent study, 5-fluorouracil (5-FU) and
5-fluoro-2′-deoxyuridine (FUDR) were found to act through
bacterial ribonucleotide metabolism to elicit their cytotoxic
effects in Caenorhabditis elegans (Garcia-Gonzalez et al.
2017), suggesting that bacteria in the host play an important
role in the response to chemotherapeutics. Similar findings
were also obtained in a different study (Scott et al. 2017).
Finally, a recent study found that the anticancer immune ef-
fects of cyclophosphamide are modulated by the gut micro-
biota. Indeed, the changes induced by this chemotherapeutic
on the gut microbiota stimulate the generation of a specific
subset of Bpathogenic^ T helper 17 cells and immune re-
sponses typically associated to this medication (Viaud et al.
2013).
Interestingly, two studies have also highlighted a role for
the microbiome in patients undergoing anti-programmed cell
death 1 protein (PD-1) immunotherapy (Gopalakrishnan
et al. 2018; Matson et al. 2018; Routy et al. 2018). The diver-
sity and composition of the microbial community differed
between responders and non-responders, accompanied by
functional differences in gut bacteria in responders (including
enrichment of anabolic pathways) (Gopalakrishnan et al.
2018). In the same study, immune profiling suggested en-
hanced systemic and antitumor immunity in responding pa-
tients with a favourable gut microbiome as well as in germ-
free mice receiving faecal transplants from responding pa-
tients (Gopalakrishnan et al. 2018). Resistance to immuno-
therapy can be attributed to abnormal gut microbiome com-
position, according to a different study. Antibiotics adminis-
tration inhibited the clinical benefit of immunotherapy in pa-
tients with cancer; moreover, faecal microbiota transplantation
(FMT) from cancer patients into germ-free mice ameliorated
the antitumor effect only when the donor was a responder,
whereas FMT from non-responding patients failed to do so
(Routy et al. 2018).
While a scarce knowledge exists on the link between the
microbiome and drug absorption/metabolism, this topic
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assumes high clinical relevance, considering that changes in
absorption and metabolism can correspond to alterations in
drug efficacy and toxicity. There are no studies so far explor-
ing the effects of microbial perturbations on psychotropic drug
pharmacokinetics and more research is warranted, especially
considered that several psychotropics have been shown to
alter the gut microbiota composition (see Table 1). Overall,
the growing evidence underlies a fascinating interaction be-
tween intestinal bacteria and drug efficacy, suggesting that
precision medicine strategies should include the intestinal mi-
crobiota as a potential treatment modifier (Jobin 2018).
Antipsychotics and gut microbiota: a general
overview
Antipsychotics are drugs used for the prophylaxis and acute
treatment of psychotic illnesses including schizophrenia and
psychosis associated with depression and mania (Gardner
et al. 2005). They also have an important role as an alternative
or adjunct to benzodiazepines in the management of the acute-
ly disturbed patient, for both tranquillisation and sedation. The
common mechanism of action of all antipsychotics is to de-
crease brain dopamine function by blocking the dopamine D2
receptors (Laruelle et al. 2005).
Analysis of faecal microbiota from 76 elderly hospitalised
patients showed that, among several therapeutic classes, the
use of antipsychotics had a strong association with gut micro-
biota composition (Ticinesi et al. 2017). In a recent study,
differences in faecal microbiota between patients with first-
episode psychosis and healthy controls, were associated with
response after up to 12 months of treatment (Schwarz et al.
2018), suggesting that the gut microbiota might be involved in
treatment response. Specifically, Lactobacillaceae and
Bifidobacteria were highly abundant in patients with first-
episode psychosis and correlated positively with severity of
psychotic symptoms and negatively with global functioning
(Schwarz et al. 2018). In a tour de force in vitro screening
study of more than 1000 drugs against 40 representative gut
bacterial strains, it was found that 24% of human-targeting
drugs inhibited the growth of at least one strain (Maier et al.
2018). Provocatively, nearly all subclasses of the chemically
diverse antipsychotics targeted a significantly more similar
pattern of species than expected from their chemical similarity,
raising the possibility that antimicrobial action may not only
manifest as side effect of antipsychotics, but also be part of
their mechanism of action (Maier et al. 2018). This hypothesis
should be ideally verified by assessing whether microbiome
manipulations (i.e. antibiotic administration) have an effect on
the efficacy of antipsychotics. Remarkably, the Maier et al.’s
study provides an exhaustive justification for the dose used in
the in vitro screening. The authors argue that, based on drug
excretion patterns from published work, the chosen
concentration of 20 μM is below the median colon concentra-
tion of the human-targeted drugs tested (Maier et al. 2018) and
therefore has translational validity. Notably, in their experi-
ment, human-targeted drugs that showed anticommensal ac-
tivity had lower plasma and estimated small intestinal concen-
trations than ones with no such activity, suggesting that more
human-targeted drugs would inhibit bacterial growth if probed
at higher doses, closer to physiological concentrations. In a
recent study in vitro, the antibacterial activity of antipsy-
chotics against Gram-positive Staphylococcus aureus and
Gram-negative Escherichia coli, Pseudomonas aeruginosa,
Klebsiella pneumoniae and Acinetobacter baumannii was in-
vestigated. Phenothiazines and thioxanthenes showed differ-
ential antibacterial activity at concentrations ranging from 64
to 1024 μg/mL, which was independent of antibiotic-
resistance patterns (Nehme et al. 2018). How these concentra-
tions translate to those found in the colon following an oral
administration of antipsychotics in humans is not clear and is
not mentioned in the study; thus, these findings might lack
translational relevance.
Typical antipsychotics and gut microbiota
Typical (first-generation) antipsychotics were first developed
in the 1950s and the first compounds to come into medical use
were the phenothiazines, such as chlorpromazine. Typical an-
tipsychotics are characterised by extrapyramidal adverse ef-
fects such as dystonia, Parkinsonian symptoms (bradykinesia,
rigidity and tremor), akathisia, tardive dyskinesia, cardiovas-
cular effects such as postural hypotension, prolactin increase
and sedation (Leucht et al. 2009).
Evidence from in vitro studies
Studies on the interaction between typical antipsychotics and
gut bacteria have been only carried out in vitro. Other ap-
proaches, such as in vivo or human observations, are missing
from literature, and one reason for this gap might be more and
more consideration is directed towards the new class of anti-
psychotics, the atypical (Skonieczna-Zydecka et al. 2018).
Thioridazine, a phenothiazine antipsychotic, has been
shown to possess antimicrobial activity in vitro against
methicillin-susceptible S. aureus (Hahn and Sohnle 2014;
Ordway et al. 2002b), vancomycin-resistant pathogenic strains
of Enterococcus species (Wainwright et al. 1999),
Mycobacterium tuberculosis (Amaral et al. 1996; Bettencourt
et al. 2000; Ordway et al. 2003; Viveiros and Amaral 2001),
Pseudomonas aeruginosa andMycobacterium avium (Viveiros
et al. 2005). Fluphenazine, another typical antipsychotic, pos-
sesses pronounced action against both Gram-positive and
Gram-negative bacteria at concentrations of 20–100 μg/mL
(Dastidar et al. 1995). Upon investigation of the antimicrobial
activity of trifluoperazine against 293 strains (from two Gram-
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Psychopharmacology
positive and eight Gram-negative genera), 46 of 55 strains of
S. aureus were inhibited by doses of 10–50 μg/mL. This drug
also inhibited strains of Shigella spp., Vibrio cholerae and
V. parahaemolyticus at concentrations of 10–100 μg/mL
(Mazumder et al. 2001). Bacillus spp. and Staphylococcus
spp. were strongly inhibited by the antipsychotic
prochlorperazine; while E. coli, Salmonella, Klebsiella and
Pseudomonas were only moderately sensitive or resistant to
the drug (Rani Basu et al. 2005). Chlorpromazine, another
typical antipsychotic, had in vitro antimycobacterial properties
(Kristiansen and Vergmann 1986; Molnar et al. 1977) and also
exerted an inhibitory synergistic effect in combination with
certain antibiotics (Amaral et al. 1992). Moreover, this medica-
tion has been shown to inhibit significantly the growth of
S. aureus (Ordway et al. 2002a) and E. coli (Amaral and
Lorian 1991; Csiszar and Molnar 1992). Keeping in mind that
these data come from in vitro bacterial cultures, it is important
to remark that a direct extrapolation and translation into the gut
microbiome scenario is not always possible.
Atypical antipsychotics and gut microbiota
Atypical antipsychotics act on numerous receptors and modu-
late several interacting transmitter systems. All atypicals (ex-
cept amisulpride) exhibit greater antagonism of 5-HT2 recep-
tors than of D2 receptors, compared with the typical agents.
Atypical drugs that do antagonise dopamine D2 receptors ap-
pear to have affinity for those in the mesolimbic system rather
than the nigrostriatal system, producing side effects of lesser
degree. Clozapine and risperidone exert substantial antago-
nism of α2-adrenoceptors, while aripiprazole is a unique drug
because it is a partial dopamine D2-receptor agonist that acts
conversely as an antagonist in regionswhere dopamine is over-
active, such as the limbic system (Bennett and Brown 2008).
Evidence from in vitro studies
The effect of olanzapine on growth of two commensal bacte-
rial strains, E. coli NC101 and Enterococcus faecalis OGIRF
was assessed in vitro across a range of supraphysiologic con-
centrations (280 to 560 μg/mL). Olanzapine completely
inhibited the growth of E. coli at concentrations above
537 μg/mL, while it did not affect the growth of E. faecalis
(Morgan et al. 2014).
Evidence from in vivo studies (rodents)
Most of the studies performed in vivo have been focusing
on two atypical antipsychotics, olanzapine and risperidone.
Administration of olanzapine for 3 weeks in rats was able
to induce specific alterations of the microbiota profile in
both males and females (Davey et al. 2012). Moreover,
administration of olanzapine in mice exacerbated the
weight gain induced by high-fat diet (Morgan et al. 2014).
Interestingly, this effect was absent under germ-free condi-
tions but emerged quickly upon microbial colonisation of
the gut, suggesting that gut microorganisms might be nec-
essary for the common adverse effect of olanzapine, weight
gain (Morgan et al. 2014). As a proof of concept, the impact
of antibiotics on olanzapine-induced weight gain was also
demonstrated. Coadministration of an antibiotic cocktail in
female rats treated with 2 mg/kg of olanzapine for 21 days,
attenuated body weight gain, uterine fat deposition, macro-
phage infiltration of adipose tissue and plasma free fatty
acid levels, all of which were increased by olanzapine alone
(Davey et al. 2013). More recently, one last experiment has
looked at microbiota changes and olanzapine administra-
tion. In this case, the prebiotic B-GOS (bimuno galacto-
oligosaccharide) was administered to adult female
Sprague-Dawley rats in coadministration with olanzapine
(2-week, daily intraperitoneal injection at a dose of
10 mg/kg) and the intake of B-GOS significantly attenuated
olanzapine-induced weight gain (Kao et al. 2018).
Although B-GOS alone increased Bifidobacteria spp., and
reduced species within the Firmicutes (Coprococcus,
Oscillibacter, C. coccoides, Roseburia intestinalis cluster,
Clos t r id ium XVI I I c lu s t e r ) and Pro t eobac t e r i a
(Escherichia/Shigella spp.) phyla, no effects of olanzapine
were observed. This is a discrepancy with other studies,
maybe due to the duration and dose of olanzapine admin-
istration and/or the method of bacterial analysis.
Importantly, additional studies are required to test whether
the bacteria affected by B-GOS would proliferate beyond
control levels with a longer duration of olanzapine admin-
istration at a clinically relevant dose. It is important to note
that sex differences might play a key role in response to
atypical antipsychotics and thus many studies to date have
been performed in females; however, more investigations
are warranted in male counterparts. The impact of
risperidone on the gut microbiota has also been investigat-
ed in vivo. Female mice treated with risperidone at a dose
of 80 μg/day over 2 months exhibited significant excess
weight gain, due to reduced energy expenditure, which cor-
related with an altered gut microbiota (Bahr et al. 2015b).
Interestingly, faecal transplant from risperidone-treated
mice into naïve recipients caused a 16% reduction in total
resting metabolic rate, attributable to suppression of non-
aerobic metabolism (Bahr et al. 2015b). Aripiprazole, an
atypical antipsychotic with a mode of action that is distinct
from most currently available antipsychotic drugs, was able
to induce marked changes in microbiota composition in rats
following a 4-week treatment at 20 mg/kg/day. The relative
abundance of various taxa including Clostridium ,
Ruminiclostridium, Intestinibacter and Eubacterium
coprostanoligens was increased by aripiprazole administra-
tion (Cussotto et al. 2018).
Psychopharmacology
Evidence from studies in humans
A recent study has looked at the association between intake of
atypical antipsychotics (AAP) and gut microbiota. In a cross-
sectional design study, faecal samples of more than 100 bipo-
lar patients were collected and analysed through 16S ribosom-
al sequencing. Participants were divided in two groups: one
group AAP-treated and one group drug-free at the time of
faecal sample collection. Atypical antipsychotics included in
the AAP cohort were clozapine, olanzapine, risperidone,
quetiapine, asenipine, ziprasodone, lurasidone, aripiprazole,
paliperidone and iloperidone. The microbiota communities
of AAP-treated and non-treated patients were significantly
separated, with AAP-treated females showing decreased spe-
cies diversity compared to non-AAP-treated females, while
males did not show significant diversity. Three specific gen-
era, Lachnospiraceae, Akkermansia and Sutterella were dif-
ferentially abundant in the two groups (Flowers et al. 2017).
While this study provides critical insight into the AAP-
mediated changes in gut microbiota, the report included no
information regarding diet, which is an important environ-
mental factor that drives the composition of gut microbiota.
Moreover, the authors observed medication-specific microbi-
ota differences, but it is not known how these translate into
functional differences. In a cross-sectional cohort study on
psychiatric patients, the effect of AAPs on the gut microbiota
was examined. Although no significant differences in micro-
biota composition were detected at baseline between AAP
users and non-users, non-AAP users showed an increase in
the bacterial genus Alistipes. AAP-treated females also had
decreased diversity compared with non-treated females
(Flowers et al. 2019). One more study in humans has investi-
gated the impact of risperidone on gut microbiota composi-
tion. In psychiatrically ill children, chronic treatment with ris-
peridone was associated with an increase in body mass index
(BMI) and a significantly lower ratio of Bacteroidetes/
Firmicutes as compared with antipsychotic-naïve psychiatric
controls. Moreover, a longitudinal observation revealed a
gradual decrease in the Bacteroidetes/Firmicutes ratio over
the ensuing months of treatment with risperidone (Bahr et al.
2015a). Although the small sample size and the fact that
polypharmacy was not taken into account, this study offers
preliminary evidence that the human gut microbiome is al-
tered in patients treated chronically with risperidone.
Antidepressants and gut microbiota:
a general overview
Antidepressants are medications used to treat symptoms of
depression, social anxiety disorder, seasonal affective disorder
and mild chronic depression, as well as other conditions
(Delgado 2004). Antidepressants can be broadly divided into
four main classes: tricyclics (TCAs), selective serotonin reup-
take inhibitors (SSRIs), monoamine oxidase inhibitors
(MAOIs) and novel compounds, some of which are related
to TCAs or SSRIs (see SNRIs, serotonin-noradrenaline reup-
take inhibitors) (Bennett and Brown 2008). The mechanism of
action is based on the Bmonoamine hypothesis^, which pro-
poses that the main cause of depression is a deficiency of the
neurotransmitters noradrenaline (NA) and serotonin (5-HT, 5-
hydroxytryptamine) in the brain. However, different classes
present different mechanisms of action: SSRIs prevent 5-HT
reuptake, TCAs inhibit NA reuptake but effects on 5-HT re-
uptake vary widely and MAOIs increase the availability of
NA and 5-HT by preventing their degradation in the presyn-
aptic terminal (Fiedorowicz and Swartz 2004).
In a cohort of elderly subjects, intake of antidepressants
was strongly associated with changes in gut microbiota com-
position (Ticinesi et al. 2017). A different population-level
analysis of gut microbiome composition found that antide-
pressants were significantly correlated to microbiome compo-
sition (Falony et al. 2016). The field of antidepressants and gut
microbiota is in constant expansion, but there is currently not
sufficient knowledge on the effect that these drugs exert on the
ecology of the gut microbiota. On the other side, a consistent
amount of research has examined the antimicrobial activity
that these compounds have against various bacterial strains
in vitro. In the following sections, evidence related to all sub-
classes of antidepressant compounds will be taken into
consideration.
Tricyclic antidepressants and gut microbiota
Evidence from in vitro studies
TCAs in general inhibit NA reuptake and some compounds
can also block 5-HT reuptake to a certain extent (Horn 1980).
All studies to date looking at TCAs and microbiota have been
performed in vitro.
Clomipramine and imipramine have been shown to pos-
sess cytotoxic effects against both human protozoan parasites
Leishmania donovani and Leishmania major (Zilberstein and
Dwyer 1984). Mandal and colleagues have analysed the anti-
microbial activity ofAmitriptyline hydrochloride against 253
bacterial strains (72 Gram-positive and 181 Gram-negative)
and 5 fungal strains in vitro. Moreover, they carried out a
mortality experiment with or without amitriptyline in mice
challenged with a virulent strain of Salmonella typhimurium
(Mandal et al. 2010). Out of 254 bacterial strains, 185 were
inhibited at different doses of amitriptyline, with
Staphylococcus spp., Bacillus spp. and Vibrio cholerae being
the most affected bacteria (Mandal et al. 2010). Regarding
fungal strains, amitriptyline inhibited both Cryptococcus
spp. and Candida albicans. Finally, in the in vivo experiment,
amitriptyline at 25μg/g and 30μg/g bodyweight significantly
Psychopharmacology
protected the mice from Salmonella typhimurium (Mandal
et al. 2010). Promethazine and imipramine have been dem-
onstrated to inhibit the growth of E. coli and Yersinia
enterocolitica through interference with plasmid replication
(Csiszar and Molnar 1992; Molnar 1988), and imipramine
was also able to inhibit the parasite Giardia lamblia
(Weinbach et al. 1992). Desipramine has been shown to be
effective against Plasmodium falciparum (Basco and Le Bras
1990; Salama and Facer 1990).
Selective serotonin reuptake inhibitors and gut
microbiota
Evidence from in vitro studies
SSRIs act, as their name indicates, predominantly by
preventing 5-HT reuptake, with little or no effect on NA re-
uptake (Stahl 1998).
SSRIs have excellent activity against Brucellae (Muñoz-
Criado et al. 1996) and they have been shown to be synergistic
in combination with antibiotics against some microorganisms
such as Corynebacterium urealyticum (Garcia-Rodriguez
et al. 1991; Munoz-Bellido et al. 1996). Interestingly, SSRIs
also affect the normal physiology of some bacteria, for exam-
ple they inhibit slime production in coagulase-negative staph-
ylococci (Munoz Criado et al. 1997) and inhibit swarming in
swarming species in Proteus (Muñoz-Criado et al. 1998).
Upon analysis of the antimicrobial activity of four SSRIs
against E. coli, sertraline was the most potent antimicrobial
compound (Bohnert et al. 2011). Since the discovery of ser-
traline as a strong antimicrobial, the research has been focused
mainly on this compound. Sertraline inhibits the growth of
S. aureus, E. coli and P. aeruginosa, and it also has synergy
in combination with antibiotics (Ayaz et al. 2015). Moreover,
sertraline has potent antifungal activity against Cryptococcus
neoformans (Rossato et al. 2016; Trevino-Rangel Rde et al.
2016; Zhai et al. 2012),Coccidioides immitis (Paul et al. 2016)
and Candida spp. (Lass-Florl et al. 2003). In a different study,
it was shown that sertraline was able to kill 97.5% of the
promastigotes of Leishmania donovani at a dose of 30 mg/L
while, at the lowest concentration (3 mg/L), it induced signif-
icant loss of viability in the promastigotes (61%) (Palit and Ali
2008). Fluoxetine had a strong dose-dependent antimicrobial
activity in vitro against L. rhamnosus and E. coli, while
escitalopram only exerted a minor antimicrobial effect on
E. coli, without affecting the growth of L. rhamnosus
(Cussotto et al. 2018).
Evidence from in vivo studies (rodents)
Evidence from our laboratory has recently shown that 4 weeks
of fluoxetine administration in drinking water in rats at a
translationally relevant dose of 10 mg/kg/day completely
inhibited the growth of Succinivibrio and Prevotella caecal
taxa (Cussotto et al. 2018). Whether the microbiome changes
influence the efficacy and/or toxicity of fluoxetine still needs
to be teased apart.
Other antidepressants and gut microbiota
Evidence from in vitro studies
Interestingly, the era of antidepressants started with
isoniazid, a compound that also has antimicrobial activity
against Mycobacterium tuberculosis and is currently used
to treat tuberculosis (Jena et al. 2014; Lei et al. 2000).
Ketamine is a non-competitive NMDA (N-methyl-D-as-
partate) antagonist that acts at the PCP (phencyclidine)
binding site in the NMDA receptor and possess a fast
onset of action as antidepressant (Bennett and Brown
2008). Ketamine showed antimicrobial activity in vitro
against six different strains of bacteria: S. aureus,
S. epidermidis, E. faecalis, S. pyogenes, P. aeruginosa
and E. coli, with S. aureus and S. pyogenes being the
most sensitive strains (Begec et al. 2013; Gocmen et al.
2008). There is currently little known regarding the ef-
fects of ketamine on gut microbiota and other classes of
antidepressants, such as MAOIs (monoamine oxidase in-
hibitors) and SNRIs (serotonin-norepinephrine reuptake
inhibitors), have not been investigated. Given the wide
range of antimicrobial effects that most antidepressants
show against different strains, it is perhaps not surprising
to speculate that SNRIs or MAOIs might exert a microbial
effect. This represents a future direction for research.
Antianxiety drugs and gut microbiota
Evidence from in vitro studies
The literature to date lacks comprehensive studies investigat-
ing the effects of antianxiety agents on the gut microbiome;
however, some studies in vitro have been carried out to assess
whether these compounds possess antimicrobial activity.
Propranolol is a beta-receptor blocker that is commonly used
to overcome the somatic symptoms of anxiety such as tachy-
cardia and palpitations (Whitlock and Price 1974). In vitro,
this compound was able to inhibit the growth of S. aureus
(Kruszewska et al. 2004) and E. coli (Hadera et al. 2018).
However, the data are divergent, as a different study showed
that propranolol did not inhibit the growth of S. aureus
(Jerwood and Cohen 2008). More research in vivo and in
humans is warranted to investigate the microbial effects of
antianxiety drugs.
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Anticonvulsants/mood stabilisers and gut
microbiota
Mood stabilisers are used to treat mood disorders,
characterised by intense and sustained mood shifts, typically
bipolar disorder, borderline personality disorder and
schizoaffective disorder. Many agents described as mood
stabilisers are also categorised as anticonvulsants (Rapoport
et al. 2009). No population-based studies have been carried
out to date looking at the influence of anticonvulsants on the
microbiome, but some preclinical data exist and are examined
in the following sections.
Evidence from in vitro studies
We have recently screened the antimicrobial activity of
lithium and valproate against E. coli and L. rhamnosus
in vitro and these two medications did not inhibit the
growth of the two bacteria (Cussotto et al. 2018).
Interestingly, however, valproate has previously been
shown to inhibit Mycobacterium smegmatis but not to af-
fect E. coli (Esiobu and Hoosein 2003). Lamotrigine
showed good antibacterial activity against Gram-positive
bacteria B. subtilis, S. aureus and S. faecalis (Qian et al.
2009) and inhibition of bacterial ribosome biogenesis
(Stokes et al. 2014). Finally, some evidence also showed
that gabapentin and topiramate possess differential antimi-
crobial activity in vitro (Kruszewska et al. 2004).
Evidence from in vivo studies (rodents)
A 4-week administration of lithium and valproate in the
chow of Sprague-Dawley rats was able to change markedly
the caecal microbiome (Cussotto et al. 2018). Bacterial rich-
ness was increased in both treatments compared to vehicle-
treated animals; moreover, at the genus level, lithium in-
creased the relative abundance of Ruminococcaceae and de-
creased Bacteroides, while valproate decreased the relative
abundance o f S24 -7 uncu l t bac t and inc r ea s ed
Ruminococcaceae (Cussotto et al. 2018). Valproate, but not
lithium, also affected the levels of SCFAs (short-chain fatty
acids) in the caecum. How these microbial changes relate to
drug efficacy is not clear. Moreover, it is also not clarified
whether these drugs affect directly the gut microbiota (i.e. they
reach the caecum) or indirectly (i.e. through gut-brain
signalling).
Opioid analgesics and gut microbiota
Opioid analgesics act to reduce the intensity and unpleasant-
ness of pain. They produce their effects by activating specific
G protein-coupled receptors in the brain, spinal cord and
peripheral nervous system (Trang et al. 2015). Acting as ago-
nists at opioid receptors, these compounds reduce neuronal
excitability and inhibit the release of pain neurotransmitters
(Conlon and Bird 2015).
Evidence from in vitro studies
Morphine did not possess antimicrobial activity against any
of the 10 microbial strains studied with the agar dilution meth-
od (Rosenberg and Renkonen 1985). Another opioid analge-
sic, tramadol, had strong bactericidal activity in vitro against
E. coli and S. epidermidis and weak antimicrobial activity
against S. aureus and P. aeruginosa (Tamanai-Shacoori et al.
2007). Methadone exerted antimicrobial activity in vitro
against S. aureus, P. aeruginosa and S. marcescens
(Sheagren et al. 1977).
Evidence from in vivo studies (rodents)
In a morphine-dependent murine model, significant shifts
in the gut microbiome and metabolome within 1 day fol-
lowing morphine treatment were detected. Morphine was
administered through the pellet implantation method, so
that plasma levels of morphine were maintained in the
0.6–2.0 μg/mL range (range observed in opioid abusers
and patients on opioids for moderate to severe pain).
Morphine-induced alterations in gut microbial composition
were associated to a significant increase in pathogenic bac-
teria and a decrease in communities associated with stress
tolerance (Wang et al. 2018). In a different study in mice,
both intermittent and sustained morphine administration
influenced the gut microbiome in a way that was causally
related to behaviours associated with opioid dependence
(Lee et al. 2018). Interestingly, subcutaneous injections of
tramadol reduce the growth of S. aureus through enhanc-
ing phagocytes and tissue inflammation; however, it does
not eliminate P. aeruginosa (Farzam et al. 2018).
Evidence from studies in humans
One study has examined the effect that opioids might have on
the gut microbiota in humans. In a cohort of cirrhotic patients,
chronic opioid use (hydromorphone N = 7, fentanyl N = 1,
methadone N = 1, morphine sulphate N = 1, oxycodone N =
23, Percocet N = 3, tramadol N = 23 and combinations of the
drugs N = 3) was associated to significant changes in
microbiome composition, with lower relative abundance of
Bacteroidaceae and Ruminococcaceae (Acharya et al. 2017).
This analysis was carried out at drug class level, and it was not
possible to discriminate between the effects induced by each
single compound.
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Drugs of abuse, alcohol, nicotine and gut
microbiota
Considering that accumulating evidence supports the role of
the gut microbiota in central nervous system (CNS) function,
the interaction between the gut microbiome and drugs of
abuse, as well as alcohol and nicotine, represents an
expanding field.
Evidence from in vitro studies
Ketamine was antimicrobial in vitro in a dose-dependent
manner against some microorganisms in propofol, which is
a strong growth-promoting factor (Begec et al. 2013). The
ketamine MIC (minimal inhibitory concentration) was
19.5 μg/mL for S. aureus and 312.5 μg/mL for E. coli and
P. aeruginosa. As ketamine has antidepressant potential, some
of its microbial effects have already been described in the
section BOther antidepressants and gut microbiota^.
Cannabis is obtained from the annual plant Cannabis
sativa and its varieties Cannabis indica and Cannabis
americana. Psychological reactions to cannabis vary widely,
depending on the predisposition of the individual and can
include euphoria, memory impairments and time-spatial sense
impairments. In vitro assays have shown that cannabis exerts
a strong antimicrobial activity against a wide range of micro-
organisms (Appendino et al. 2008; M M Ali et al. 2018;
Nissen et al. 2010).
Nicotine, one of the main components of tobacco, possesses
all the characteristics of a drug of dependence. It modulates
dopamine activity in the midbrain, particularly in the
mesolimbic system,which promotes the development andmain-
tenance of reward behaviour (Rice and Cragg 2004). Two stud-
ies in vitro have evaluated the antimicrobial activity of nicotine.
The psychotropic compound was active against E. coli,
P. aeruginosa and S. faecalis at a dose of 2 μg/μL (Idrees
Zaidi et al. 2012) and against Listeria monocytogenes and
Viridans streptococci at a dose of 10 μg/mL (Pavia et al. 2000).
Evidence from in vivo studies (rodents)
Th e g u t m i c r o b i o t a o f r a t s t h a t u n d e r g o i n g
methamphetamine-induced conditioned place preference is
different from that of control animals. Moreover, the faecal
microbial diversity is slightly higher in methamphetamine-
t r e a t ed r a t s . The p rop i ona t e - p roduc i ng genu s
Phascolarctobacterium is attenuated in methamphetamine-
treated rats and the family Ruminococcaceae is increased in
the same group (Ning et al. 2017). In addition, the short-chain
fatty acid propionate was decreased in the faecal matter of rats
that received methamphetamine (Ning et al. 2017). The
microbiome might play a role also in cocaine addiction: ad-
ministration of antibiotics in mice induced an enhanced
sensitivity to cocaine reward and an enhanced sensitivity to
the locomotor-sensitising effects of repeated cocaine adminis-
tration (Kiraly et al. 2016). Regarding cannabis, recent evi-
dence has shown that modifications in the gut microbiota con-
sequential to diet-induced obesity are prevented in mice treat-
ed chronically with Δ9 tetrahydrocannabinol (THC), the
major psychoactive constituent of cannabis (Cluny et al.
2015).
Alcohol generally exerts on cells in the CNS a depressant
effect that is probably mediated by particular membrane ion
channels and receptors (Whitlock and Price 1974). Alcohol
enhances inhibitory GABAA-stimulated flux of chloride
through receptor-gated membrane ion channels, a receptor
subtype effect that might be involved in the motor impairment
caused by alcohol (Abrahao et al. 2017). Exposure to 4 weeks
of chronic intermittent vaporised ethanol in mice markedly
altered the gut microbiota, increasing the levels of Alistipes
and decreasing Clostridium IV, Dorea and Coprococcus
(Peterson et al. 2017). In a mouse model of alcoholic liver
disease, Bacteroidetes and Verrucomicrobia were increased
in mice fed alcohol compared with a relative predominance
of Firmicutes in control mice (Yan et al. 2011). Several other
studies in rodents have highlighted a correlation between
chronic alcohol consumption, leading to liver disease, and
microbiome composition (Fouts et al. 2012; Guarner et al.
1997; Yan and Schnabl 2012). Interestingly, corroborating
the idea that the gut microbiome might play a role in alcohol
consumption, two dietary means have been used as modula-
tors of the gut microbiome during alcohol consumption.
Saturated and unsaturated dietary fats (Kirpich et al. 2016),
for example, as well as rhubarb extract (Neyrinck et al. 2017),
have been shown to modulate the changes in gut microbiota
induced by alcohol intake.
Finally, the psychotropic nicotine administered in
drinking water influenced the gut microbiota composition
in a sex-specific manner in mice. In treated females,
Christensenellaceae, Anaeroplasmataceae and unassigned
families in the orders Bacillales were significantly re-
duced. Famil ies such as Turic ibacteraceae and
Peptococcaceae were largely increased in male counter-
parts (Chi et al. 2017).
Evidence from studies in humans
In a human cohort, cocaine users displayed a higher relative
abundance of Bacteroidetes than non-users (Volpe et al.
2014). The composition and diversity of intestinal microbiota
in a cohort of 50 patients with substance use disorders (SUD;
of which 52% on heroin and 30% on methamphetamine)
was significantly different from those of healthy controls.
The relative abundance of Thauera, Paracoccus and
Prevotellawas significantly higher in SUD patients compared
to healthy participants (Xu et al. 2017). The intestinal
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microbiota of SUD people would change independently of the
type of substance abused, suggesting that the global switch of
lifestyle due to SUD in general could be responsible for the
changes in microbiome. Importantly, almost all patients with
SUDs are involved in alcohol and tobacco addiction, which
may also account for the microbiome effects (Xu et al. 2017).
The microbiome of chronic marijuana users displayed a
Prevotella/Bacteroides ratio that was 13-fold lower than the
one of non-users (Panee et al. 2018). A combination of THC
and cannabidiol (CBD) has been shown to mitigate experi-
mental autoimmune encephalomyelitis (EAE) by altering the
gut microbiome (Al-Ghezi et al. 2017).
Regarding alcohol, the mucosa-associated colonic
microbiome was altered in alcoholics compared to control
participants. Specifically, the alcoholics with dysbiosis had
lower median abundances of Bacteroidetes and higher ones
of Proteobacteria. Moreover, these alterations were correlated
with high levels of serum endotoxin in a subset of the samples
(Mutlu et al. 2012). Two similar studies have demonstrated
that alcohol-dependent subjects have an increased intestinal
permeability which is linked to significant microbiome alter-
ations (de Timary et al. 2015; Keshavarzian et al. 2009;
Leclercq et al. 2014). Bacterial overgrowth was found in the
jejunum of patients with chronic alcohol abuse (Bode et al.
1984). In cirrhotic patients, the proportion of phylum
Bacteroidetes was significantly reduced, whereas
Proteobacteria and Fusobacteria were highly enriched com-
pared to healthy controls. Moreover, Enterobacteriaceae,
Veillonellaceae and Streptococcaceae were prevalent in pa-
tients with cirrhosis at the family level (Chen et al. 2011).
Nicotine consumption and also smoking cessation induced
profound changes in the gut microbiome in humans, with an
increase of Firmicutes and Actinobacteria and decrease of
Bacteroidetes and Proteobacteria at the phylum level. In addi-
tion, smoking cessation induced an increase in microbial di-
versity (Biedermann et al. 2013). The effect of tobacco smoke
on the oral and gut microbiome has been recently investigated
in a human cohort, where tobacco smokers displayed a higher
relative abundance of Prevotella, lowered Bacteroides and
lower Shannon diversity in tobacco smokers compared to con-
trols (Stewart et al. 2018).
Xanthines and gut microbiota
The three xanthines caffeine, theophylline and theobromine
occur naturally in plants. These compounds have complex
and incompletely elucidated actions, which include inhibition
of phosphodiesterase (the enzyme that breaks down cyclic
AMP), effects on intracellular calcium distribution and norad-
renergic function (Bennett and Brown 2008). All xanthines
stimulate mental activity to different extents and their effects
vary according to the mental state and personality of the sub-
ject (Bennett and Brown 2008).
Evidence from in vitro studies
Xanthines were screened against several microbial strain and
all compounds displayed antimicrobial activity, with caffeine
being the most effective compound (Raj and Dhala 1965). The
morphology of Aerobacter aerogenes and A. cloacae was af-
fected by caffeine (Raj and Dhala 1965). Coffee also inhibited
the growth of E. coli and E. faecalis in vitro (Tatsuya and
Kazunori 2013). However, this is not the first study showing
that caffeine has antimicrobial activity in vitro, as a previous
experiment had already demonstrated this concept (Daglia
et al. 2007).
Evidence from in vivo studies (rodents)
A two-week administration of cocoa’s theobromine to
healthy adult rats was shown to induce marked changes in
gut microbiota composition. Specifically, rats that received a
10% cocoa-containing diet had lower intestinal counts of
E. coli, whereas rat that received a 0.25% theobromine-
containing diet had lower counts of Bifidobacterium spp.,
Streptococcus spp. and Clostridium histolyticum-C.
perfingens group compared to normal-fed rats (Martín-
Peláez et al. 2017). Consumption of fermented green tea, con-
taining theophylline, was able to restore the changes in gut
microbiota composition associated to diet-induced obesity in
mice (Seo et al. 2015). In a different study, consumption of
500 μL/day of coffee for three consecutive days in specific-
pathogen-free mice induced E. coli and Clostridium spp.
counts to decrease significantly (Tatsuya and Kazunori
2013). Caffeine-rich Pu-erh tea remodelled the intestinal
dysbiosis in mice with metabolic syndrome (Gao et al.
2018). Specifically, Akkermansia muciniphila and
Faecalibacterium prausnitzii were speculated to be the key
gut bacterial links between the Pu-erh tea treatment and met-
abolic syndrome at the genus and species levels (Gao et al.
2018). Chronic coffee consumption in diet-induced obese rats
was accompanied by decreased abundance of Clostridium
Cluster XI and increased levels of Enterobacteriaceae.
Moreover, SCFAs (short-chain fatty acids) were largely in-
creased in the coffee-fed rats (Cowan et al. 2014). It is impor-
tant to note that studies on the effects of caffeine on gut mi-
crobiota are not always consistent, for example in a different
experiment on rats, 8 weeks of coffee consumption did not
alter the gut microbiota composition (Cowan et al. 2013). A 3-
week regimen with oral administration of 0.7 mg/kg/day in
mice decreased Lactobacillus ratios compared to controls, but
none of the other taxa were affected (Kleber Silveira et al.
2018).
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Evidence from studies in humans
Caffeine consumption has received much attention in recent
years in relation to microbiome alterations often associated to
metabolic disorders. Consumption of 3 cups of coffee daily
for 3 weeks in healthy volunteers did not alter faecal profiles
of the dominant microbiota, but increased the population of
Bifidobacterium spp. (Jaquet et al. 2009). Moreover, in some
subjects, there was a specific increase in the metabolic activity
of Bifidobacterium spp. (Jaquet et al. 2009).
Conclusion
In Harry Potter, the basilisk hidden in the Chamber has the
power to petrify people and poses a threat for Hogwarts
School: what happens in the Chamber will affect the entire
school and vice versa. Similarly, increasing evidence suggests
that the gut microbiome affects and can be affected by various
chemical compounds. This bidirectional influence is more and
more studied in relation to psychotropic compounds. Initially
thought to work only in the brain, in recent years, psychotro-
pic compounds have shown antimicrobial activity in vitro and/
or the ability to affect the gut microbiome in vivo. It is evident
from the data reviewed here that different microbial effects
have been attributed to psychotropic compounds, ranging
from medications to drugs of abuse, caffeine and alcohol.
The challenge now is to assess the functional role of these
microbial changes. It is important to note that the results up
to now come mainly from in vitro experiments on isolated
strains and further clinical/preclinical experimentation is re-
quired to understand whether, for example drug-mediated mi-
crobial changes are complementary mechanisms of action or
are responsible for the side effects associated to these com-
pounds. Moreover, in terms of polypharmacy, more work is
needed to investigate the impact of combinations of drugs on
the microbiome. As our knowledge of the gut microbiome
increases, the major lesson is that the Chamber of Secrets
should be taken into account in future pharmacokinetic and
pharmacodynamics analysis of known drugs and become part
of the safety pharmacology of drugs in development. It is not
bizarre to think that in the future microbiome measures will
form part of clinical practice to investigate either the efficacy
or side effects of psychotropic compounds. This field of re-
search may also influence selection of individuals for clinical
trials. Clearly it will need to be integrated, in a larger systems
biology approach, to other -omics and biomarker measures in
psychiatric patients.
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